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The introduction (Chapter I) of this thesis provides the rationale for
islet immunoisolation and transplantation. The aim of islet transplantation is
to provide the diabetic patient with an endogenous ource of insulin in order
to delay the onset and progression of diabetic complications. In clinical trials,
immunosuppressive therapy is applied to circumvent immune destruction of
the islets. Effective immunosuppression, however, is associated with serious
side effects which make it doubtful whether such an approach will ever be
applicable in large numbers of diabetic patients as a sound alternative for
insulin treatment. This is the main reason to concentrate on approaches
which fundamentally differ from the conventional approach of suppressing
the host's immune system. One such approach which has the potential to be
developed into a widely applicable therapy for diabetics is immunoisolation
of islets in a membrane permeable for glucose, insulin and nutrients but not
for humoral and cellular components of the immune system. This technique
allows for successful transplantation of islets derived from xenogenic, and
thus unlimited, donor sources in the absence of immunosuppressive
medication. A historical review of the transplantation of insulin producing
cells in semipermeable membranes is presented. Presently, there are three
different technical approaches for transplantation of immunoisolated islets.
These approaches are: (i) immunoisolation in extravascular macrocapsules,
(ii) immunoisolation in intravascular macrocapsules and (iii)
immunoisolation in extravascular microcapsules. The features of these
different approaches are discussed in the perspective of future application i
man. Of those techniques, microencapsulation offers the best option for
being developed into a technique widely applicable in diabetic patients with
a fair chance ofsuccess.
A review of the results of experimental studies with
microencapsulated islets is presented in the second part of the introduction
(Chapter f . These results vary considerably which usually is interpreted to be
the consequence of problems associated with the biocompatibiliry of the
capsule materials. Consequently, the majority of studies 0n
microencapsulated islets somehow seem to focus on the problem of capsule










of capsules and the metabolic control by the grafrs, have gained little
n0 attenuon,
In Chapter II we have reviewed the obstacles on the road to
I transplantation of microencapsulated islets. These obstacles can be
in three categories. The first regards the technical aspecrs of the
uction process. Limiting factors are the insufficient abiliry to produce
capsules with an adequate production rate, and insufficient insight in
factors determining the optimal chemical and mechanical properties of
capsules. The second category regards functional aspects of the
lated islets, such as the limitations of the transplantation site
the absence of a physiologic insulin response of encapsulated islets to
clevated blood glucose levels. The third category regards the fact that sr.rrvival
dmes of encapsulated islet grafts are still limited to several weeks or months,
which mainly is explained by fibrotic overgrowth induced by
bioincomoatibiliw of the caosule membrane. This overview describes these
obstacles, and thereby summarizes the requirements for successfi,rl c inical
application f encapsulated islet transplantation.
ln Cltapter III we present the rationale for the studies included in
this thesis (Chapters IV-XI). In view of the obstacles mention ed in Chapter II,
our aimes were to identify the obstacles which presendy Prevent the clinical
application of microencapsulated islets, and to develop strategies to overcome
these obstacies. ln the course of time we found that some properties of the
capsules which were initially categorized as 'technical aspects of the
production process' are ciosely related to problems initially categorized as
'functional survival of the graft'. Thus, in presenting our results we have
chosen a rational scquence of chapters, rather than maintaining the strict
categories. The rationale of each individual study is given below in the
summary of each chapter.
Graft failure of alginate-polylysine microencapsulated islets is often
interpreted as the consequence of a non-specific foreign body reaction against
the microcapsules, initiated by impurities present in crude alginate. The aim
of the srudies presented in Chapter IVwas to investigate if purification of the
alginate improves the biocompatibiliry of alginate-polylysine microcapsules.
7
?
rAlginate was purified by filtration, extraction and precipitation.
Microcapsules prepared of crude or purified alginate were implanted in the
peritoneal caviry of normoglycemic AO-rats and retrieved at I, 2, 3, 6, 9, and
12 months after implantation. 'With crude alginate, all capsules were
overgrown within one month after implantation. Vith purified alginate,
however, the portion of capsules overgrown was usually below 100/0, even at
12 months after implantation. A1l recipients of islet allografts in capsules
prepared of purified alginate became normoglycemic within 5 days after
implantation, but hyperglycemia occurred after 6 to 20 weeks. Vith IVGTT
and OGTI all recipients had impaired glucose tolerance and insulin
responses were virtually absent. After graft failure, capsules were retrieved
(B0-100%) by peritoneal lavage. Histologically, the percentage of overgrown
capsules was usually below 10% and maximally 31%. This small portion
cannot explain the occurrence of graft failure. The immunoprotective
properties of the capsules were confirmed by similar if not identical survival
times of encapsulated islet allo- and isografts. Our results show that
purification of the alginate improves the biocompatibility of alginate-
polylysine microcapsules. Nevertheless, graft survival was still limited.
In search of other processes than overgrowth contributing to graft
failure we have studied the islets in non-overgrown capsules at several time
points after allotransplantation in the rar (Chapter 14. All recipients of islet
allografts became normoglycemic. Grafts were retrieved at four and eight
weeks after implantation, and at 15.3 x 2.3 weeks postimplant i.a. rwo weeks
after the mean time period at whiclt graft failure occurred. Overgrowth of
capsules was complete within four weeks postimplant. It was usually
restricred to less than 10olo of the capsules. During the first four weeks of
imprlantation, 1+0a/o of the initial number of islets was lost. -fhereafter, we
observed a decrease in frrncti<ln rather than in numbers of islet.s, as illustrated
by a decline in the er uiuo glucose induced insulin response. At four and eight
weeks postimplant, Beta-cell replication was ten-fold higher in encapsulated
islets than in islets in the normal pancreas. But, these high replication rates
were insufficient to prevent a progressive increase in the percentage of

















islets, which indicates insufficient nutrition as a major causative factor. Our
study demonstrates that not only capsular overgrowth but also an imbalance
berween Beta-cell birth and Beta-cell death contributes to the failure of
encapsulated islet grafts. Our observations indicate that we should focus on
finding or creating a transplantation site which, more than the unmodified
peritoneal cavity, permits for close contact berween the blood and the
encapsulated islet tissue.
As a consequence of its large volume, a microencapsulated islet graft
can be implanted only into the peritoneal caviry. The graft volume can be
reduced by applying small capsules. However, reduction of the capsules
diameter holds a certain risk as with smaller capsules more islets may be
found to protrude from the capsules. 'We have developed a lectin binding
assay which, after encapsulation, specifically labels islets or parts of islets
which are insufficiently immunoprotected as a consequence of inadequare,
and particularly incomplete, encapsulation (Chapter V|. \fith this assay we
found that a reduction of the capsule diameter from 800 pm to 500 pm was
associated with an increase in the perc€nrage of inadequately encapsulated
islets from 6.3 + l.2o/o ro 24.2 t l.5o/o.The in uiuo significance of this finding
was investigated by perfbrming allotransplantations with large (700-800 pm)
and small (400-500 pm) capsule diameters. Vith large capsule diameter islet
grafts all recipients (n = 5) became normoglycemic for 7-16 weeks, while with
small capsule diameter islet grafts only one of seven recipients became
normoglycemic. The in uiuo significance of inadequate encapsulation was
further substantiated by our finding that most large capsules were freely
floating in the peritoneal cavity without any cell adhesion, while the vasr
majority of smdl capsules was found to be adherelrt ro rhe surface of intra-
abdorninal organs and infiltrated by immune cell elemenrs characteristic for
both an allograft reacrion and a foreign body reaction. We conclude that
successful application of small capsule diameters requires further study to
determine which factors in the encapsulation procedure should be modified
in order to reduce rhe number of inadequate small capsules.
The observation that not all but only a porrion of all alginate-







physical imperfections of individual capsules rarher than the chemical
composition of the material applied is responsible for inducing insufficienr
biocompatibiliry and thereby fibrotic overgrowth of those capsules. The study
presented in Chaprcr WI investigates factors influencing the adequacy of
encapsulation of pancreatic islets. W'e applied our lectin binding assay and
found that the number of inadequate, and particularly incomplere, capsules
is influenced by the following factors. (i) A capsule diameter of 800 pm is
associated with a lower percentage of inadequate capsules than smaller (500
pm, 600 pm) or larger (1800 pm) capsules. (ii) The composition of the
alginate. Alginate is composed of mannuronic acid (M) and guluronic acid
(G). A high- rather than low-G content of the alginate is associated with a
lower percentage of inadequate capsules. This can at least in part be explained
by smaller ranges of swelling and subsequent shrinkage during the
encapsulation procedure. (iii) An increase in viscosiry by applying a higher
alginate concentration compensates for a low-G content. This effect of
increased viscosiry cannot be explained by a reduced range of swelling and
shrinkage during the encapsulation procedure. Ve conclude that one should
preferably use alginates with a high-G content and a viscosity near the
filtration limit in order to minimize the number of inadequate capsules.
Little is known of the influence of the differences in G-content in
alginates on biocompatibiliry of alginate-Pll capsules. Therefore, we have
investigated in uiuo the effect of the G content of the alginate on the
biocompatibiliry of the capsules (Chapter VIII. Capsules prepared of
commercially available alginates with either a high- or an intermediate-G
content were implanted in the peritoneal caviry of rats and retrieved one
month later for histological evaluation. The fibrotic reaction was more severe
against high-G alginate capsules than to intermediate-G alginate capsules
which are ussually applied for islet encapsulation (Chapter IV and Lj. The
majoriry of the high-G capsules proved to be overgrown and adherent o the
abdominal organs while with intermediate-G alginate most capsules were
found freely floating in the peritoneal caviry and free of any adhesion of cells.
This was not caused by the alginate as such but rather by inadequate binding
of lrigh-G alginate to PLL since in the absence of PLL, i.e. with beads instead
of capsules, no fibrotic reaction was observed. As high-G alginates have
beneficial effects for islet encapsulation, efforts should be made to apply
polycations which more effectively interact with high-G dginate than PLL.
Presently used single needle air-driven droplet generators are
incapable of producing sufficient numbers of islet conraining droplets in a
sufficiently short time period to allow for successfully grafting alginate-
polylysine encapsulated islets in large animals or humans. Therefore, we have
designed an air-driven multineedle droplet generator, which increases the
production rate by simultaneously producing multiple droplets (Chapter I$.
Although we have tested a four-needle device, the construction is such that
the number of needles, and thereby the production rate, can be readily
extended. The production rate can be further extended by increasing the
number of islets per milliliter alginate in the reservoir.'S7hen tested with 500
pm and 800 pm capsules, an increase in the number of islets per milliliter
alginate was found to be associated with an increase in the number of
inadequately encapsulated islets in a diameter dependent fashion. 'When
small instead of large capsules are produced from a given volume of alginate,
larger numbers of capsules are obtained but also a larger portion of
inadequate capsules. 'W'ith 10,000 islets per millimeter alginate, these
combined effects can be calculated to result in a rwofold increase in the
production rate of adequate capsules when 500 pm instead of 800 pm
capsules are produced. So, substantial upscaling of the production can be
achieved by combining an increase in the number of needles with a decrease
in the capsule diameter.
Intraperitoneal transplantation of encapsulated islets can restore
normoglycemia in diabetic recipients but not normal glucose rolerance nor
normal insulin responses to a physiologic stimulus. The study presented in
Chapter Xinvestigates whether the intraperitoneal implantation site as such
contributes to the interference with optimal transport kinetics berween the
islets and the bloodstream. lnsulin was infused into the peritoneal caviry of
conscious and freely noving rats in doses of 20, 40 and B0 pMimin during
15 minutes, to mimic the gradual release of insulin from an encapsulated, i.e.




rof insulin levels and it took 30 minutes until glucose levels had dropped
significantly. Vith 40 and B0 pM/min insulin infusions, there was a dose
dependent rise of insulin and decrease of glucose levels. V/hen compared to
intraportal infusions with the same insulin dosages, however, they were
strongly delayed and reduced as well as prolonged. Similar results were
obtained when inulin instead of insulin was intraperitoneally infused, which
indicates that the transport of insulin from the peritoneal caviry to the blood
stream is mainly by passive diffusion. \With view on the clinical efficacy of the
bioartificial pancreas, our findings indicate that we should focus on finding
or creating a transplantation site which, more than the unmodified peritoneal
cavity, permits for close contact between the bloodstream and the
encapsulated islet tissue.
An intraperitoneally located and prevascularized ePTFE solid
support is potentially a suitable transplantation site for encapsulated
pancreatic islets, since it allows both for the implantation of a large volume
islet graft in the immediate viciniry of blood vessels, and for its complete
removal. The study presented in Chapter Xlinvestigates the efficacy of solid
supports for the implantation of non-encapsulated islet isografts in
streptozotocin diabetic rat recipients. These solid supports were always coated
with a-FGF, since we found that this growth factor enhances the
neovascularization. The success rates of 5 pl (group A) and 10 pl (Group B)
islet isografts in solid supports were compared to the success rates of 5 Fl
(Group C) and 10 pl (Group D) islet isografts implanted in the unmodified
peritoneal cavity. Four of 7 rats in Group A and all 7 rats in group B became
normoglycemic for at least 6 months. Only 2 of B rats in group C and 4 oi
11 rats in group D showed normoglycemia, which lasted for at least 6 months
in none of 2 in group C and 3 of 4 in group D. Because of the low success
rates in groups C and D, intravenous and oral glucose testing were restricted
to the successful recipients in groups A and B. Glucose tolerance was found
to be proportional to the grafted islet volume but, expectedly, in both groups
the glucose tolerance and the insulin responses were somewhat lower than in
controls. Thus, the prevascularized ePTFE solid support rather than the
unmodified peritoneal cavity is an efficacious transplantation site, potentially
suitable for encapsulated islets.
The results of our studies are discussed in the perspective of other
studies in the general discussion (Chapter XII).Ve discuss the prerequisites
for long-term survival of the encapsulated islet graft. These not only include
a capsule which elicits a minimal foreign body reaction, but also a normal
balance berween Beta-cell birth and death in the encapsulated islets. Also, we
discuss the different approaches to improve the kinetics of the glucose
induced insulin responses in the recipients. W'e suggest hat it is likely that
longer graft survival times and better insulin responses than currently
achieved with implantation in the unmodified peritoneal caviry can be
achieved when encapsulated islets are transplanted in well vascularized sites
such as the prevascularized ePTFE solid supports.
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